This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery

This study has been completed.
Information provided by (Responsible Party):
University of Miami Identifier:
First received: March 15, 2007
Last updated: December 14, 2016
Last verified: December 2016

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Radiation therapy may also make tumor cells more sensitive to cisplatin. Giving radiation therapy together with cisplatin after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase I trial is studying the side effects and best dose of whole-abdominal radiation therapy when given together with cisplatin in treating patients with stage III or stage IV endometrial cancer that has been removed by surgery.

Condition Intervention Phase
Endometrial Cancer Radiation: Vaginal Brachytherapy Drug: Cisplatin Radiation: Whole Abdominal Radiation [WAR] Therapy Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium

Resource links provided by NLM:

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Toxicity as assessed by GOG Common Toxicity Criteria [ Time Frame: Study duration ]
  • Recommended phase II dose of whole-abdominal radiotherapy [ Time Frame: Study duration ]

Enrollment: 12
Study Start Date: May 2002
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Whole-Abdominal Radiation Therapy and Chemotherapy Radiation: Vaginal Brachytherapy
High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
Drug: Cisplatin
Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
Radiation: Whole Abdominal Radiation [WAR] Therapy
Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
Other Name: WAR

Detailed Description:


  • Determine a recommended phase II dose of adjuvant whole-abdominal radiotherapy when administered with cisplatin in patients with optimally debulked stage III or IV carcinoma of the endometrium.

OUTLINE: This is a dose-escalation study of whole-abdominal radiotherapy (WAR).

Patients receive 3 courses of standard chemotherapy comprising carboplatin IV and paclitaxel IV. Beginning within 6 weeks after completion of standard chemotherapy, patients receive cisplatin IV over 30-60 minutes and undergo a single fraction of WAR on day 1. Treatment with cisplatin and WAR repeats weekly for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients may undergo standard vaginal brachytherapy beginning no earlier than the last course of standard chemotherapy or no later than 1 week before the start of cisplatin and WAR.

Cohorts of 3-6 patients receive escalating doses of WAR until the recommended phase II dose (RPTD) is determined. The RPTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the RPTD.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Diagnosis of endometrial cancer, including any of the following cellular types:

    • Papillary serous carcinoma
    • Clear cell carcinoma
    • Adenocarcinoma
  • Stage III or IV disease

    • No evidence of extra-abdominal extension of disease (e.g., groin nodes, lung, or supraclavicular nodes)
  • Has undergone total-abdominal hysterectomy, surgical removal of any present fallopian tube and ovary, and resection of any palpable lymph nodes in the pelvis and para-aortic region (or surgical sampling of these nodal regions if no palpable nodes were present) within the past 6 weeks

    • Peritoneal washings must have been collected for cytological evaluation
    • Must have ≤ 1 cm residual disease after surgery


  • Karnofsky performance status 60-100%
  • Life expectancy ≥ 6 months
  • WBC ≥ 3,000/mm^3
  • Granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine < 2.0 mg/dL
  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • Lactate dehydrogenase < 3 times ULN
  • Gamma glutamyl transferase < 3 times ULN
  • SGPT and SGOT < 3 times ULN
  • Alkaline phosphatase < 3 times ULN
  • No other malignant tumor within the past 5 years


  • See Disease Characteristics
  • No prior radiotherapy to the whole abdomen and/or pelvis/vagina
  • No systemic chemotherapy within the past 5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00448643

United States, Florida
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Study Chair: Aaron H. Wolfson, MD University of Miami Sylvester Comprehensive Cancer Center
  More Information

Responsible Party: University of Miami Identifier: NCT00448643     History of Changes
Other Study ID Numbers: 20020138
Study First Received: March 15, 2007
Last Updated: December 14, 2016

Keywords provided by University of Miami:
endometrial adenocarcinoma
endometrial clear cell carcinoma
endometrial papillary carcinoma
stage III endometrial carcinoma
stage IV endometrial carcinoma

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Antineoplastic Agents processed this record on August 23, 2017